Swisspreneur Show

EP #477 - Simon Michel: Swiss Politics & Running a Large Medtech Business

Feb 23, 2025
Simon Michel, CEO of Ypsomed and member of Switzerland’s National Council, shares his journey in the medtech industry. He discusses the evolution of Ypsomed from its roots in insulin delivery to broader chronic care solutions. The conversation dives into the challenges of balancing R&D in Switzerland with manufacturing abroad, the strategy behind going public, and the necessity for political involvement to support entrepreneurs. Michel also reflects on maintaining Swiss values while pursuing global expansion.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Dual Strategy Challenges

  • Ypsomed's dual B2B and B2C strategy presents a challenge for valuation.
  • The B2B delivery systems business enjoys high margins, while B2C diabetes care faces competition.
ANECDOTE

Swiss HQ Advantages

  • Ypsomed keeps its headquarters in Switzerland due to its favorable tax environment and strong R&D talent pool.
  • Manufacturing is located abroad in lower-wage countries like Germany and China.
ANECDOTE

IPO for Growth

  • Ypsomed went public in 2004 to fund a new manufacturing site in Solothurn.
  • The IPO provided the necessary capital for expansion and growth.
Get the Snipd Podcast app to discover more snips from this episode
Get the app